FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for ABRILADA (adalimumab-afzb) from Pfizer Laboratories Div Pfizer Inc, authorizing its use as a Humira biosimilar.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• ABRILADA (ADALIMUMAB-AFZB)

Snippet

SUPPL AP for ABRILADA (ADALIMUMAB-AFZB)